Immunotherapy for Hodgkin Lymphoma in India: Nivolumab, Pembrolizumab and When They Are Used
Quick answer: Classical Hodgkin lymphoma is usually treated first with combination chemotherapy, sometimes with radiotherapy. PD-1 immunotherapy such as nivolumab or pembrolizumab is mainly used when the lymphoma comes back or does not respond, and newer trials are testing nivolumab alongside first-line chemotherapy. In September 2026 India’s oncology expert committee reviewed a proposal for nivolumab with AVD chemotherapy in untreated stage III or IV disease, so approved uses in India depend on the current CDSCO label.
Medically reviewed by: [Reviewer name, qualification] | Last reviewed: [DD Month YYYY]
Why Hodgkin lymphoma responds to checkpoint inhibitors
Hodgkin lymphoma is a cancer of the lymphatic system. Its hallmark cells, called Reed-Sternberg cells, carry high levels of proteins that engage the PD-1 pathway, a braking system on T-cells. PD-1 inhibitors release that brake so the immune system can act against the lymphoma cells. This biological feature is why Hodgkin lymphoma was among the first cancers where these medicines showed clear activity. Our article on immune checkpoint inhibitors explains the mechanism in plain language.
First-line treatment: chemotherapy remains the foundation
For most people with newly diagnosed classical Hodgkin lymphoma, treatment starts with multi-drug chemotherapy regimens, often with radiotherapy for selected early-stage disease. Doctors choose the regimen by stage, symptoms, age and other health factors. The AVD regimen mentioned in current regulatory discussions combines doxorubicin, vinblastine and dacarbazine. Our guide to types of chemotherapy describes how these drugs work, and our piece on immunotherapy versus chemotherapy explains why they are often combined rather than chosen against each other.
A published review notes that up to a quarter of people with classical Hodgkin lymphoma are resistant to first-line chemotherapy or relapse afterwards. That is the group where immunotherapy has had the greatest impact.
Where PD-1 immunotherapy is used
Relapsed or refractory disease
For relapsed or refractory classical Hodgkin lymphoma, standard care has traditionally been second-line chemotherapy followed, for suitable patients, by high-dose chemotherapy with an autologous stem cell transplant. PD-1 inhibitors have changed that landscape: they can be given before a transplant to help achieve remission, or afterwards in selected people. Pembrolizumab and nivolumab are both used for relapsed disease in India, but approvals are specific, so ask which label your doctor is relying on. Stem cell transplantation is carried out at specialised transplant centres; Denvax does not perform transplants.
Newly diagnosed advanced disease: a proposal under review
The SWOG S1826 phase 3 trial compared nivolumab plus AVD with brentuximab vedotin plus AVD in advanced-stage classical Hodgkin lymphoma. Published commentary describes early data as favouring nivolumab-AVD. On the strength of that trial, the manufacturer presented a proposal to India’s oncology expert committee on 29 September 2026 for nivolumab with AVD in adults and in patients aged 12 and older with previously untreated stage III or IV disease, and the committee’s notes refer to a phase 4 study in India with a significant number of participants aged 12 to 18. Whether a final label has been issued and exactly what it says should be checked with your oncologist, because committee recommendations and final approvals are not the same thing.
What a modified or low-dose schedule means
Because of cost, some Indian specialists have reported using modified or lower-dose nivolumab schedules in relapsed Hodgkin lymphoma. One retrospective report of 20 patients treated between 2016 and 2021 noted that 15 received a modified protocol because of financial limitations, and it flagged possible delayed immune-related side effects around the time of transplant in some patients. Case reports also describe low-dose nivolumab as a bridge to transplant. These are small, specialist experiences, not a substitute for the approved schedule. Please never adjust or stretch doses on your own to save money; if cost is the barrier, tell your oncologist so the plan can be reviewed safely.
Side effects to know about
PD-1 inhibitors can cause immune-related effects such as thyroid problems, rash, diarrhoea or colitis, hepatitis and lung inflammation. Because Hodgkin lymphoma often affects younger adults, some reactions can matter for planning around transplant and fertility; discuss these topics with your treating team before starting. When immunotherapy is combined with chemotherapy, chemotherapy effects such as low blood counts and nausea also apply. Our pages on immunotherapy side effects and low white blood cell counts during cancer treatment are good starting points.
What drives the cost
We do not quote totals, because they depend on the regimen. The main factors are the choice of medicine (originator nivolumab or the Indian biosimilar launched in January 2026, where your oncologist considers it suitable), dose and vials per infusion, number of cycles, the chemotherapy and any radiotherapy that accompany it, day-care charges, monitoring tests and scans, and insurance coverage. See our upcoming guide to nivolumab pricing in India for published vial prices and our immunotherapy cost overview. Always ask the hospital for an itemised estimate.
Getting an opinion at Denvax
Denvax Cancer Center in Vasant Vihar, New Delhi, has treated over 25,000 patients since 2004 and offers chemotherapy, radiotherapy, targeted therapy and dendritic cell immunotherapy. A confirmed lymphoma diagnosis requires a biopsy and imaging done at a diagnostic facility, as Denvax does not offer testing or diagnostics. Bring your pathology report, PET-CT or other scans and your treatment history. Our doctors can talk through which treatments may be relevant and what to ask your lymphoma specialist. For background on blood cancers more broadly, see our guide to blood cancer symptoms and costs.
Frequently asked questions
Is immunotherapy the first treatment for Hodgkin lymphoma?
Usually not. Chemotherapy, sometimes with radiotherapy, remains the standard starting point. PD-1 inhibitors are mainly used for relapsed or refractory disease, and combinations with first-line chemotherapy are being reviewed by regulators.
Which immunotherapy medicines are used for Hodgkin lymphoma in India?
Nivolumab and pembrolizumab are the two PD-1 inhibitors most commonly discussed for classical Hodgkin lymphoma. Approved indications are set by the current CDSCO label, so confirm yours with your oncologist.
Is nivolumab approved for newly diagnosed Hodgkin lymphoma in India?
A proposal for nivolumab with AVD in untreated stage III or IV classical Hodgkin lymphoma was reviewed by India’s oncology expert committee on 29 September 2026. Ask your oncologist whether a final label is in force before relying on it.
Can immunotherapy replace a stem cell transplant?
Immunotherapy is sometimes used to prepare for a transplant or after it, but whether a transplant is still needed depends on your response and overall plan. This is decided by your lymphoma and transplant team.
Is a lower-dose nivolumab schedule safe?
Small Indian reports describe modified schedules, but the evidence is limited and delayed immune-related effects have been noted. Do not change a prescribed dose without your oncologist’s guidance.
Results may vary. Consult your oncologist. This article is for general information and is not medical advice.
Review your lymphoma reports with a Denvax doctor
Bring your pathology report, scans and treatment history to Denvax Cancer Center, 18 Poorvi Marg, Vasant Vihar, New Delhi 110057.
अपनी पैथोलॉजी रिपोर्ट, स्कैन और इलाज के रिकॉर्ड के साथ Denvax Cancer Center में परामर्श के लिए संपर्क करें।
- Dendritic Cell Therapy Side Effects: What Patients Report and How They Are Managed
- Immunotherapy for Kidney Cancer in India: Options, Who May Be Eligible and Cost Factors
